Brought to you by 
Cara Therapeutics partners CR845 with Maruishi in Japan
25 Jul 2018
Executive Summary
Cara Therapeutics Inc. (candidates for pain, inflammation, and itching) has licensed Maruishi Pharmaceutical Co. Ltd. (perioperative and disinfecting/antiseptic products) exclusive Japanese rights to develop, manufacture, and market its most advanced compound CR845 for acute postoperative pain and uremic pruritus (itching in patients with end-stage renal disease).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cara Therapeutics partners CR845 with Maruishi in Japan
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice